Journal article
Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal
Abstract
This paper presents a summary of the evidence review group (ERG) report into the clinical and cost-effectiveness of romiplostim for the treatment of adults with chronic immune or idiopathic thrombocytopenic purpura (ITP) based upon a review of the manufacturer’s submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission’s evidence came from two …
Authors
Mowatt G; Boachie C; Crowther M; Fraser C; Hernández R; Jia X; Ternent L
Journal
Health Technology Assessment, Vol. 13, No. Suppl 2 Article 9, pp. 63–68
Publisher
National Institute for Health and Care Research
DOI
10.3310/hta13suppl2-09
ISSN
1366-5278